Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.

Inclusion Criteria: * Documented histologic or cytologic diagnosis of advanced metastatic NSCLC, advanced/unresectable pancreatic cancer, or metastatic colorectal cancer. * Cachexia, defined by BMI \<20 kg/m2 with involuntary weight loss of \>2% within 6 months prior to screening or Involuntary weight loss of \>5% within 6 months prior to screening irrespective of BMI or If medical record documentation is unavailable, patient's report will suffice to estimate involuntary body weight loss.; * Will receive the following for non-small cell lung cancer: * a platinum + pemetrexed ± pembrolizumab or * a platinum + nab paclitaxel or paclitaxel ± pembrolizumab or * pembrolizumab alone * Will receive the following for pancreatic cancer: * FOLFIRINOX or * Nab-Paclitaxel + Gemcitabine * Gemcitabine * Will receive the following for colorectal cancer: * FOLFOX +/- Biologic (Bevacizumab or Cetuximab/Panitumumab) or * FOLFIRI +/- Biologic (Bevacizumab or Cetuximab/Panitumumab) or * FOLFOXIRI +/- Biologic (Bevacizumab or Cetuximab/Panitumumab) or * Pembrolizumab for MSI-H • Will be entering the study at the first or second cycle of their current course of anti-cancer treatment/ therapy. * Adequate renal and liver function. * Signed informed consent. Exclusion Criteria: * All other forms of cancers not specified above unless currently considered cured (\>5 years without evidence of recurrence). * Planned radiation therapy as part of the primary anti-tumor therapy reg…